Akashi DMD drug candidate Fast Tracked

|By:, SA News Editor

The FDA grants Fast Track designation to Akashi Therapeutics' lead product candidate HT-100 (delayed-release halofuginone) as a potential treatment to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne Muscular Dystrophy (DMD). The agency has also designated HT-100 an Orphan Drug. The product candidate is currently being evaluated in a Phase 1b/2a clinical trial.

Related tickers: (PTCT) (SRPT) (RNA)